Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  JAMA ophthalmology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaophthalmol.2015.4070PMID 26513684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

  2016cited by this paper
• Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age‐related macular degeneration: a randomised, prospective trial

  2015cited by this paper
• Systematic Review of Safety Across the Phase 2 and 3 Clinical Trials of Intravitreal Aflibercept Injection in Neovascular Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, and Diabetic Macular Edema

  2015cited by this paper
• Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results.

  2015cited by this paper
• Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

  2015cited by this paper
• Intravitreal Aflibercept for Diabetic Macular Edema

  2015cited by this paper
• Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.

  2014cited by this paper
• Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

  2014cited by this paper
• Revolution to a new standard treatment of diabetic macular edema.

  2014cited by this paper
• A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study).

  2014cited by this paper
• Intravitreal aflibercept for diabetic macular edema.

  2014cited by this paper
• Anti-vascular endothelial growth factor for diabetic macular oedema.

  2014cited by this paper
• Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

  2014cited by this paper
• Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

  2014cited by this paper
• Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration

  2014cited by this paper
• SYSTEMIC SAFETY OF RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Meta-analysis of Randomized Trials

  2014cited by this paper
• Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

  2014cited by this paper
• Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.

  2014cited by this paper
• Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.

  2014cited by this paper
• A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.

  2013cited by this paper
• Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4)

  2013cited by this paper
• Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

  2013cited by this paper
• Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

  2013cited by this paper
• What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

  2013cited by this paper
• Current treatments in diabetic macular oedema: systematic review and meta-analysis

  2013cited by this paper
• Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.

  2013cited by this paper
• Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study.

  2013cited by this paper
• Meta-analysis examining the systemic safety profile of intravitreal ranibizumab injections in AMD, RVO and DME

  2013cited by this paper
• Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

  2013cited by this paper
• Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt Versus Deferred Laser Treatment: Three-Year Randomized Trial Results

  2013cited by this paper
• Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

  2012cited by this paper
• CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS

  2012cited by this paper
• Long-term effects of ranibizumab on diabetic retinopathy severity and progression.

  2012cited by this paper
• Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

  2012cited by this paper
• Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results.

  2012cited by this paper
• Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

  2012cited by this paper
• TWO-YEAR RESULTS OF A RANDOMIZED TRIAL OF INTRAVITREAL BEVACIZUMAB ALONE OR COMBINED WITH TRIAMCINOLONE VERSUS LASER IN DIABETIC MACULAR EDEMA

  2012cited by this paper
• A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.

  2012cited by this paper
• A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.

  2011cited by this paper
• Comparison of Intravitreal Bevacizumab Alone or Combined with Triamcinolone versus Triamcinolone in Diabetic Macular Edema: A Randomized Clinical Trial

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design.

  2011cited by this paper
• Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

  2011cited by this paper
• Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study.

  2010cited by this paper
• Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

  2010cited by this paper
• Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.

  2009cited by this paper
• Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.

  2009cited by this paper
• Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.

  2009cited by this paper
• Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Intravitreal Bevacizumab versus Combined Bevacizumab-Triamcinolone versus Macular Laser Photocoagulation in Diabetic Macular Edema

  2008cited by this paper
• Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)

  2007cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

  2003cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994cited by this paper
• GrADE: an emerging consensus on rating quality of evidence and strength of recommendations

  year unknowncited by this paper

• Sustained intraocular delivery of nintedanib via PLGA implant eradicates pathological angiogenesis in retinal neovascularization

  2026cites this paper
• Systemic and local vascular features in branch retinal vein occlusion: analysis of the retinal age gap and crossing pattern

  2026cites this paper
• Adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema in Taiwan: a comparative cohort study

  2025cites this paper
• Polymer-based gene-drug co-delivery system effectively inhibits pathologic retinal neovascularization through dual anti-inflammatory and anti-neovascular actions.

  2025cites this paper
• Intravitreal vascular endothelial growth factor inhibitor systemic and renal toxicity registry

  2025cites this paper
• Estimated Five-year Risk of Systemic Cardiovascular Events With Anti-VEGF Injections in Neovascular Age-related Macular Degeneration.

  2025cites this paper
• A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database

  2025cites this paper
• Diabetic Retinopathy Preferred Practice Pattern®.

  2025cites this paper
• Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study

  2025cites this paper
• Effect of intravitreal Bevacizumab on coagulation profile of patients with diabetic retinopathy

  2025cites this paper
• Intravitreal vascular endothelial growth factor inhibitors and cardiovascular adverse drug reactions: Added value of the data of the French pharmacovigilance spontaneous reporting assessment.

  2025cites this paper
• Patient with severe proliferative diabetic retinopathy and comorbidity: analysis of solved and unsolved problems in diabetic retinal involvement diagnosis and treatment from the point of real-world clinical practice and clinical guidelines

  2025cites this paper
• Consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME).

  2025cites this paper
• Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease.

  2025cites this paper
• The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy

  2025cites this paper
• Changes of hard exudates in response to intravitreal injection of ranibizumab and lipid lowering medications in diabetic macular edema

  2025cites this paper
• Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

  2025cites this paper
• Short-term efficacy of ranibizumab on macular vascular lesions in Jammu and Kashmir, India: a prospective study

  2025cites this paper
• Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases

  2025cites this paper
• Advancements in the Treatment of Diabetic Macular Edema: Current Strategies and Future Directions

  2024cites this paper
• Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study.

  2024cites this paper
• Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis

  2024influential citation
• Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an OHDSI Network Study.

  2024cites this paper
• Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents

  2024cites this paper
• Cardiovascular risk in anti-VEGF treatment of neovascular age-related macular degeneration.

  2024cites this paper
• Systemic Arterial and Venous Thrombotic Events Associated with Anti-Vascular Endothelial Growth Factor Injections: A Meta-Analysis.

  2024cites this paper
• Advancing treatment of retinal disease through in silico trials

  2023cites this paper
• Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor

  2023cites this paper
• Vascular endothelial growth factor inhibition in retinal vein occlusion does not associate with cardiovascular morbidity and mortality.

  2023cites this paper
• Effects of Topical or Intravitreal Application of Anti-Vascular Endothelial Growth Factor on Density of Intestinal Blood Vessels of Mice

  2023cites this paper
• Homeostasis and dyshomeostasis of the retina

  2023cites this paper
• Guidelines from an expert panel for the management of diabetic macular edema in the Malaysian population.

  2023cites this paper
• Optical coherence tomography in the management of diabetic macular oedema.

  2023cites this paper
• Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration

  2023cites this paper
• From randomised controlled trials to real-world data: Clinical evidence to guide management of diabetic macular oedema.

  2023cites this paper
• Long-Term Change in Renal Function After Intravitreal Anti-VEGF Treatment for Diabetic Macular Edema: A 2-Year Retrospective Cohort Study

  2023cites this paper
• Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice

  2023cites this paper
• Modulation of Hypoxia-Inducible Factors and Vascular Endothelial Growth Factor Expressions by Superfood Camu-Camu (Myrciaria dubia) Treatment in ARPE-19 and Fetal Human RPE Cells

  2023cites this paper
• Counseling Patients about Rare but Serious Harms: The Importance of Absolute as well as Relative Risks.

  2023cites this paper
• Difficulty in Assessing the Systemic Adverse Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy.

  2023cites this paper
• The multifunctional human ocular melanocortin system.

  2023cites this paper
• Age-related macular degeneration and cardiovascular disease in US population: an observational study

  2023cites this paper
• Systemic Adverse Events Among Patients With Diabetes Treated With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

  2023cites this paper
• VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration

  2023cites this paper
• Safety of intravitreal anti VEGF injections in diabetic macular edema

  2023cites this paper
• Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema

  2023cites this paper
• Intravitreal ranibizumab injection is associated with an increased risk of chronic kidney disease: a population-based study in Taiwan

  2023cites this paper
• Intravitreal Vascular Endothelial Growth Factor Inhibitor Use and Renal Function Decline in Patients with Diabetic Retinopathy

  2022cites this paper
• Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis

  2022cites this paper
• Temporal fluctuations of cardiovascular parameters after intravitreal injections

  2022cites this paper
• Ranibizumab Response in Diabetic Macular Edema at Mansoura Ophthalmology Center

  2022cites this paper
• Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review

  2022cites this paper
• Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema

  2022cites this paper
• A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes

  2022cites this paper
• Electrophysiological Evaluation of Macular Photoreceptor Functions in Patients with Choroidal Neovascular Membranes

  2022cites this paper
• Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature

  2022cites this paper
• IS A DECREASED NITRIC OXIDE CONCENTRATION AFTER TRIAMCINOLONE ACETONIDE INTRAVITREAL INJECTION ONE OF THE REASONS FOR INTRAOCULAR PRESSURE RISE?

  2022cites this paper
• Study on BCVA, CMT, CME, Curative Effect, and Prognostic Value of DR Sufferers Based on Surgical Therapy Combined with VEGF Therapy at Different Times

  2022cites this paper
• Risk of dialysis in patients receiving intravitreal anti–vascular endothelial growth factor treatment: a population-based cohort study

  2022cites this paper
• Cardiovascular and mortality risk with intravitreal vascular endothelial growth factor inhibitor in patients with diabetic retinopathy.

  2022cites this paper
• Efficacy and Safety of Aflibercept Therapy for Diabetic Macular Edema: A Systematic Review and Meta-Analysis

  2022cites this paper
• Factors predicting the treatment frequency of ranibizumab injections during the second year in diabetic macular edema

  2022cites this paper
• Examining the Relationship Between Diabetic Macular Edema, and Obstructive Sleep Apnea

  2022cites this paper
• Examining the Relationship Between Diabetic Macular Edema, and Obstructive Sleep Apnea

  2022cites this paper
• Cardiovascular morbidity and all-cause mortality in patients with retinal vein occlusion: a Danish nationwide cohort study

  2022cites this paper
• Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double‐masked, vehicle‐controlled study

  2022cites this paper
• Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization

  2021cites this paper
• The Effects of Intravitreal Agents on Systemic Vascular Diseases in Patients with Diabetic Retinopathy

  2021cites this paper
• Are visual disturbances (excluding diabetic retinopathy) more common in geriatric DM patients? Are they risks factor for the progression of disability?

  2021cites this paper
• Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review

  2021cites this paper
• The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

  2021cites this paper
• Changes of plasma nitric oxide, endothelin-1, and blood coagulation following intravitreal conbercept

  2021cites this paper
• Frequency of intravitreal anti-vascular endothelial growth factor injections and risk of death: a systematic review with meta-analysis.

  2021cites this paper
• Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization

  2021cites this paper
• Diagnosis and Management of Ophthalmic Complications of Diabetes

  2021cites this paper
• Investigation of the Trend of Selecting Anti-Vascular Endothelial Growth Factor Agents for the Initial Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

  2021cites this paper
• Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema

  2021cites this paper
• Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report

  2021cites this paper
• Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization

  2021cites this paper
• Data Science in Translational Vision Science and Technology

  2021cites this paper
• Vitreoretinal Society of India practice pattern survey 2020: Medical retina

  2021cites this paper
• Review of intravitreal vascular endothelial growth factor inhibitor toxicity and report of collapsing focal and segmental glomerulosclerosis with thrombotic microangiopathy in patient with age-related macular degeneration

  2021cites this paper
• Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence

  2021cites this paper
• Does conventional laser photocoagulation still have a place in the treatment of diabetic macular edema?

  2021cites this paper
• RANTES as a novel biomarker for atherogenic dyslipidemia and metabolic disturbances in patients with Type 2 Diabetes

  2021cites this paper
• Human Platelets Take up Anti-VEGF Agents

  2021cites this paper
• Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

  2021cites this paper
• Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction

  2021cites this paper
• Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients

  2021cites this paper
• Comparative Risk of Arterial Thromboembolic Events Between Aflibercept and Ranibizumab in Patients with Maculopathy: A Population-Based Retrospective Cohort Study

  2021cites this paper
• Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration

  2021cites this paper
• The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients

  2021cites this paper
• Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

  2021cites this paper
• Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema

  2021cites this paper
• Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.

  2020cites this paper
• Surgical and Nonsurgical Trauma

  2020cites this paper
• We will ‘ROCK’ you? The role of Rho kinase inhibitors in eye care

  2020cites this paper
• A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion

  2020cites this paper
• Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy

  2020cites this paper
• [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Situation August 2019].

  2020cites this paper